Literature DB >> 25015863

High prevalence of atypical hyperplasia in the endometrium of patients with epithelial ovarian cancer.

Marjanka J J M Mingels1, Rina Masadah2, Yvette P Geels3, Irene Otte-Höller4, Ineke M de Kievit5, Jeroen A W M van der Laak4, Maaike A P C van Ham3, Johan Bulten4, Leon F A G Massuger3.   

Abstract

OBJECTIVES: The aim of the present study is to determine the prevalence of endometrial premalignancies in women diagnosed with epithelial ovarian cancer (EOC).
METHODS: Endometrial and ovarian specimens of 186 patients with EOC were retrospectively selected using the nationwide pathology network and registry, and sections were comprehensively reviewed: 136 (73%) serous, 19 (10%) endometrioid, 15 (8%) mucinous, seven (4%) clear cell, and nine (5%) undifferentiated. Immunohistochemical phenotypes were compared for patients with serous EOC with concurrent endometrial pathology.
RESULTS: In 31%, endometrial (pre)malignancy was found: carcinoma in 3%, endometrial intraepithelial carcinoma (EIC) in 4%, and atypical hyperplasia in 24%. Atypical hyperplasia was found in 47% of endometrioid EOCs but in 7% to 33% of other subtypes. Body mass index was higher concurrent to atypical hyperplasia (P=.001). Serous EOC and EIC immunophenotypes were comparable, whereas atypical hyperplasia was expressed differently.
CONCLUSIONS: Apart from synchronous endometrial carcinoma, endometrial premalignancies should be taken into account when determining optimal treatment for women diagnosed with EOC. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Atypical hyperplasia; Endometrial intraepithelial carcinoma; Endometrium; Epithelial ovarian cancer

Mesh:

Year:  2014        PMID: 25015863     DOI: 10.1309/AJCPTGJOPXUW6RVO

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  1 in total

1.  Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.

Authors:  Courtney D Bailey; Rebecca Previs; Bryan M Fellman; Tarrik Zaid; Marilyn Huang; Alaina Brown; Ahmed Enbaya; Nyla Balakrishnan; Russell R Broaddus; Diane C Bodurka; Pamela Soliman; Nicole D Fleming; Alpa Nick; Anil K Sood; Shannon Neville Westin
Journal:  Int J Gynecol Cancer       Date:  2020-10-29       Impact factor: 3.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.